Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
Cancer Research and Treatment. 2018;50(1):95-102 
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Lung Cancer. 2017;110:63-67
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion
Lung Cancer. 2019;127:59-65
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy
Clinical Pharmacology & Therapeutics. 2016;100(3):212-214
13 EGFR-mutation analysis, treatment and outcomes in newly diagnosed patients with non-small cell lung cancer (NSCLC): a single-institution retrospective review
Lung Cancer. 2012;75:S5
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Clinical Lung Cancer. 2016;17(5):350-361
MA15.01 Strong PD-L1 Expression Predicts Poor Response and de Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients with EGFR Mutation
Journal of Thoracic Oncology. 2018;13(10):S407
P1.04-18 PD-L1 Expression and its Correlation with Tumor TNM Stage in Patients with Non-Small Cell Lung Cancer
Journal of Thoracic Oncology. 2018;13(10):S532
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
Lung Cancer. 2016;99:79-87
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
Lung Cancer. 2016;93:9-16